Australian pharma to benefit from trade agreement with South Korea

Published: 6-Jan-2014
Regulatory Pharmaceutical

Tariffs for Australian pharmaceuticals going to South Korea to be cut by 8%


Australia and South Korea concluded negotiations for a free trade agreement in December that could see tariffs for Australian pharmaceuticals slashed by as much as 8%.

Under the agreement Australia’s fourth-largest trading partner South Korea will eliminate tariffs for Australian manufactured goods including pharmaceuticals and vitamins over the next seven years.

See more

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Read more
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche

Trending Articles

  1. Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia. Production capacity to meet European market demand for pharmaceutical ampoules. Facility brings around 180 new jobs to the region
  2. The IND advantage: why early derisking is a strategic imperative for complex biologics As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
  3. Nestlé Health Science and IdB partner to bring VOWST to Europe Nestlé Health Science and IdB Holding have signed a licensing agreement to seek EMA approval for VOWST, the only FDA-approved oral live biotherapeutic for recurrent C. diff prevention
  4. FDA Form 483 flags falsified records and live bird infestation at Dabur India OTC plant A FDA inspection report issued in January 2026 has revealed widespread CGMP failures at Dabur India's Dadra and Nagar Haveli facility, including manipulated microbiology data, fraudulent equipment logs and unsanitary storage conditions
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    NICE approval is not enough: why the UK’s next medicines challenge is operational delivery A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Regulatory

AMR Bio urges US policymakers to make infection prevention a core AMR strategy

Submitted ahead of PACCARB's 27th public meeting, AMR Bio's recommendations call for topical antimicrobials such as MRSA-active XF-73 to receive federal support alongside conventional antibiotic development
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

NICE approval is not enough: why the UK’s next medicines challenge is operational delivery

A medicine is not truly accessible until it can be manufactured, procured, stocked, prescribed, dispensed and delivered reliably. That distinction is becoming increasingly important, says Varun Cruz, founder of NEUVIOR
Regulatory

What to expect from a regulatory inspection: An NSF expert guide

Prepare with confidence. NSF’s expert guide shows what inspectors look for, common pitfalls and how to ensure lasting inspection readiness
Subscribe now